Launch Date
10/21/2022 at 4:00 am EST
Credit Amount
0.5
Credit Expires
10/21/2023
Within the Mycophenolate Risk Evaluation and Mitigation Strategy (REMS) system, one of the key requirements is that health care providers (HCPs) monitor mycophenolate-treated patients of reproductive potential for pregnancy both prior to initiation of treatment as well as routinely throughout the treatment course. HCPs are also responsible for appropriately responding to any pregnancies that do occur in the setting of mycophenolate treatment. It is imperative that HCPs are thoroughly educated on providing appropriate counsel to these patients as well as the importance of reporting the pregnancy to the Mycophenolate Pregnancy Registry, which was established with the goal of analyzing mycophenolate-exposed pregnancies and their outcomes in an effort to advance understanding of mycophenolate exposure in utero.
In part three of this REMS CME Outfitters Snack series, Lisa Coscia, RN joins host/moderator Dr. Steven Gabardi to provide guidance on appropriate monitoring strategies for pregnancy as well as the importance of reporting any pregnancies that do occur to the Mycophenolate Pregnancy Registry.
At the end of this CME/CE activity, participants should be able to monitor patients of reproductive potential for pregnancy to report to Mycophenolate Pregnancy Registry.
This activity is supported by an independent educational grant from the Mycophenolate REMS Group. This activity is intended to be fully compliant with the Mycophenolate REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
Primary care physicians, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, and physicians specializing in transplant medicine, OB/GYN, surgery, rheumatology, immunology and cardiology
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gibardi reports no financial relationships to disclose.
Ms. Coscia reports the following financial relationships: Grants: Veloxis Pharmaceuticals, Inc. (Educational grant to her institution)
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.